Ono Pharmaceutical 향후 성장

Future 기준 점검 0/6

Ono Pharmaceutical 의 수익과 수익은 각각 연간 1.7% 및 0.4% 감소할 것으로 예상됩니다. EPS는 연간 0.4% 만큼 쇠퇴할 것으로 예상됩니다. 자기자본이익률은 3년 후 7.6% 로 예상됩니다.

핵심 정보

-0.4%

이익 성장률

-0.42%

EPS 성장률

Pharmaceuticals 이익 성장	13.4%
매출 성장률	-1.7%
향후 자기자본이익률	7.64%
애널리스트 커버리지	Good
마지막 업데이트	23 Jul 2026

최근 향후 성장 업데이트

분석 기사 • May 12

Analyst Estimates: Here's What Brokers Think Of Ono Pharmaceutical Co., Ltd. (TSE:4528) After Its Yearly Report

Investors in Ono Pharmaceutical Co., Ltd. ( TSE:4528 ) had a good week, as its shares rose 7.1% to close at JP¥2,479...

분석 기사 • Feb 05

Ono Pharmaceutical Co., Ltd. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Ono Pharmaceutical Co., Ltd. ( TSE:4528 ) investors will be delighted, with the company turning in some strong numbers...

Recent updates

분석 기사 • May 12

Analyst Estimates: Here's What Brokers Think Of Ono Pharmaceutical Co., Ltd. (TSE:4528) After Its Yearly Report

Investors in Ono Pharmaceutical Co., Ltd. ( TSE:4528 ) had a good week, as its shares rose 7.1% to close at JP¥2,479...

분석 기사 • Feb 05

Ono Pharmaceutical Co., Ltd. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Ono Pharmaceutical Co., Ltd. ( TSE:4528 ) investors will be delighted, with the company turning in some strong numbers...

분석 기사 • Feb 02

A Look At The Intrinsic Value Of Ono Pharmaceutical Co., Ltd. (TSE:4528)

Key Insights Ono Pharmaceutical's estimated fair value is JP¥2,771 based on 2 Stage Free Cash Flow to Equity Current...

분석 기사 • Dec 02

Ono Pharmaceutical (TSE:4528) Has Affirmed Its Dividend Of ¥40.00

Ono Pharmaceutical Co., Ltd. ( TSE:4528 ) has announced that it will pay a dividend of ¥40.00 per share on the 22nd of...

분석 기사 • Nov 01

Analysts Have Made A Financial Statement On Ono Pharmaceutical Co., Ltd.'s (TSE:4528) Half-Year Report

Ono Pharmaceutical Co., Ltd. ( TSE:4528 ) investors will be delighted, with the company turning in some strong numbers...

분석 기사 • Sep 19

이익 및 매출 성장 예측

TSE:4528 - 애널리스트 향후 추정치 및 과거 재무 데이터 (JPY Millions)
날짜	매출	이익	자유현금흐름	영업현금흐름	평균 애널리스트 수
3/31/2029	457,819	69,387	82,423	96,892	11
3/31/2028	444,471	62,513	83,506	96,762	12
3/31/2027	454,302	70,982	117,970	128,032	12
3/31/2026	515,785	69,767	83,551	136,821	N/A
12/31/2025	509,345	62,404	72,116	125,635	N/A
9/30/2025	503,668	48,495	49,061	102,300	N/A
6/30/2025	496,732	42,926	31,762	85,019	N/A
3/31/2025	486,871	50,047	74,469	82,459	N/A
12/31/2024	487,331	74,025	75,689	92,625	N/A
9/30/2024	484,298	95,127	91,943	108,662	N/A
6/30/2024	500,331	120,953	105,249	121,111	N/A
3/31/2024	502,672	127,977	89,831	110,660	N/A
12/31/2023	498,070	127,611	91,301	106,044	N/A
9/30/2023	489,199	124,875	97,371	115,354	N/A
6/30/2023	460,481	115,064	98,429	116,894	N/A
3/31/2023	447,187	112,723	145,113	159,610	N/A
12/31/2022	428,951	111,555	137,391	149,495	N/A
9/30/2022	403,985	96,568	93,387	102,437	N/A
6/30/2022	380,720	85,922	78,395	88,151	N/A
3/31/2022	361,361	80,519	49,552	61,829	N/A
12/31/2021	345,781	73,558	38,233	53,343	N/A
9/30/2021	332,887	81,866	60,412	83,032	N/A
6/30/2021	321,734	78,003	47,401	70,321	N/A
3/31/2021	309,284	75,425	53,684	73,977	N/A
12/31/2020	302,054	74,364	53,088	72,011	N/A
9/30/2020	293,886	66,737	55,742	70,596	N/A
6/30/2020	293,351	64,870	58,824	78,232	N/A
3/31/2020	292,420	59,704	51,712	74,157	N/A
12/31/2019	290,736	60,233	N/A	73,947	N/A
9/30/2019	293,247	55,510	N/A	66,058	N/A
6/30/2019	291,374	52,633	N/A	58,850	N/A
3/31/2019	288,634	51,539	N/A	66,774	N/A
12/31/2018	284,463	51,978	N/A	67,269	N/A
9/30/2018	284,785	57,919	N/A	61,700	N/A
6/30/2018	272,165	53,746	N/A	48,716	N/A
3/31/2018	261,836	50,284	N/A	15,727	N/A
12/31/2017	256,522	54,760	N/A	28,754	N/A
9/30/2017	248,517	53,884	N/A	40,205	N/A
6/30/2017	246,953	53,887	N/A	53,650	N/A
3/31/2017	244,797	55,793	N/A	74,450	N/A
12/31/2016	236,710	48,270	N/A	44,743	N/A
9/30/2016	207,707	36,225	N/A	32,972	N/A
6/30/2016	183,345	29,206	N/A	16,805	N/A
3/31/2016	160,284	24,979	N/A	12,842	N/A
12/31/2015	140,927	16,449	N/A	29,716	N/A
9/30/2015	143,697	21,568	N/A	31,169	N/A

애널리스트 향후 성장 전망

수입 대 저축률: 4528 의 수익은 향후 3년간 감소할 것으로 예상됩니다(연간 -0.4%).

수익 vs 시장: 4528 의 수익은 향후 3년간 감소할 것으로 예상됩니다(연간 -0.4%).

고성장 수익: 4528 의 수익은 향후 3년간 감소할 것으로 예상됩니다.

수익 대 시장: 4528 의 수익은 향후 3년간 감소할 것으로 예상됩니다(연간 -1.7%).

고성장 매출: 4528 의 수익은 향후 3년 동안 감소할 것으로 예상됩니다(연간 -1.7%).

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: 4528의 자본 수익률은 3년 후 7.6%로 낮을 것으로 예상됩니다.

성장 기업 찾아보기

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2026/07/30 11:38
종가	2026/07/30 00:00
수익	2026/03/31
연간 수익	2026/03/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Ono Pharmaceutical Co., Ltd.는 19명의 분석가가 다루고 있습니다. 이 중 12명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
Atsushi Seki	Barclays
Koichi Mamegano	BofA Global Research
Hidemaru Yamaguchi	Citigroup Inc

Ono Pharmaceutical 향후 성장

Future 기준 점검 0/6

핵심 정보

최근 향후 성장 업데이트

Price target increased by 7.3% to JP¥2,458

Analyst Estimates: Here's What Brokers Think Of Ono Pharmaceutical Co., Ltd. (TSE:4528) After Its Yearly Report

Ono Pharmaceutical Co., Ltd. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Price target increased by 7.2% to JP¥1,929

Price target increased by 11% to JP¥1,896

Price target increased by 7.4% to JP¥1,709

Recent updates

Ono Pharmaceutical Rolls Out Phylo AI Platform Across Drug Discovery Teams

Final dividend of JP¥40.00 announced

Price target increased by 7.3% to JP¥2,458

Full year 2026 earnings: Revenues exceed analysts expectations while EPS lags behind

Ono Pharmaceutical Stock in Focus as Phase 3 Sapablursen Trial Begins for Polycythemia Vera

Ono Pharmaceutical Co., Ltd. Announces Oral Presentation Of New Data From The Phase 2 Clinical Study Of ONO-4578 In Certain Gastric Cancers At The ASCO 2026 Annual Meeting

Ono Pharmaceutical Co., Ltd. to Report Q1, 2027 Results on Jul 31, 2026

Analyst Estimates: Here's What Brokers Think Of Ono Pharmaceutical Co., Ltd. (TSE:4528) After Its Yearly Report

Full year 2026 earnings: Revenues exceed analysts expectations while EPS lags behind

Ono Pharmaceutical Delivers Strong Profits for FY2025 While Guiding for Softer Revenue in FY2026

Ono Pharmaceutical Co., Ltd., Annual General Meeting, Jun 18, 2026

Ono Pharmaceutical Co., Ltd. to Report Fiscal Year 2026 Results on May 08, 2026

Ono Pharmaceutical Co., Ltd. Submits Application for Approval of Ripretinib in Japan

Upcoming dividend of JP¥40.00 per share

Now 20% undervalued

Ono Pharmaceutical Co., Ltd. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Third quarter 2026 earnings: EPS and revenues exceed analyst expectations

A Look At The Intrinsic Value Of Ono Pharmaceutical Co., Ltd. (TSE:4528)

Price target increased by 7.2% to JP¥1,929

Price target increased by 11% to JP¥1,896

Price target increased by 7.4% to JP¥1,709

Ono Pharmaceutical (TSE:4528) Has Affirmed Its Dividend Of ¥40.00

First half dividend of JP¥40.00 announced

Ono Pharmaceutical Co., Ltd. to Report Q3, 2026 Results on Feb 02, 2026

Analysts Have Made A Financial Statement On Ono Pharmaceutical Co., Ltd.'s (TSE:4528) Half-Year Report

New major risk - Revenue and earnings growth

Now 21% undervalued

Ono Pharmaceutical Co., Ltd. Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study ofromVIMZA (Vomselinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 2025

Ono Pharmaceutical Co., Ltd. Announces Encouraging Efficacy Signals of ONO-2808, a S1P5 Receptor Agonist, in an Interim Analysis of Ongoing Phase 2 Clinical Trial in Patients with Multiple System Atrophy

Upcoming dividend of JP¥40.00 per share

Ono Pharmaceutical (TSE:4528) Will Pay A Dividend Of ¥40.00

Ono Pharmaceutical Co., Ltd. Receives European Commission Approval of ROMVIMZA (Vimseltinib) for the Treatment of Tenosynovial Giant Cell Tumor (TGCT)

Ono Pharmaceutical (TSE:4528) Has Announced A Dividend Of ¥40.00

Ono Pharmaceutical Co., Ltd. to Report Q2, 2026 Results on Oct 30, 2025

Ono Pharmaceutical (TSE:4528) Has Announced A Dividend Of ¥40.00

First quarter 2026 earnings: Revenues exceed analysts expectations while EPS lags behind

Deciphera Pharmaceuticals, Llc Announces Positive Chmp Opinion Forromvimza™? (Vimseltinib) for the Treatment of Tenosynovial Giant Cell Tumor (Tgct)

Final dividend of JP¥40.00 announced

Full year 2025 earnings: EPS misses analyst expectations

New major risk - Revenue and earnings growth

Ono Pharmaceutical Co., Ltd. to Report Q1, 2026 Results on Aug 01, 2025

Ono Pharmaceutical Co., Ltd. Presents Positive Results from Pivotal Trial in U.S. Patients with Relapsed or Refractory PCNSL At 2025 Asco Annual Meeting

Full year 2025 earnings: EPS misses analyst expectations

Ono Pharmaceutical Co., Ltd., Annual General Meeting, Jun 19, 2025

Consensus EPS estimates increase by 16%, revenue downgraded

Price target decreased by 11% to JP¥1,725

Upcoming dividend of JP¥40.00 per share

Ono Pharmaceutical Co., Ltd. to Report Fiscal Year 2025 Results on May 08, 2025

New major risk - Revenue and earnings growth

New minor risk - Profit margin trend

First half dividend of JP¥40.00 announced

Ono Pharmaceutical Co., Ltd. to Report Q3, 2025 Results on Feb 03, 2025

Consensus EPS estimates fall by 17%

Second quarter 2025 earnings: EPS and revenues exceed analyst expectations

Upcoming dividend of JP¥40.00 per share

Ono Pharmaceutical Co., Ltd. to Report Q2, 2025 Results on Oct 31, 2024

Ono Pharmaceutical Co., Ltd. Announces U.S. Food and Drug Administration Accepts for Priority Review Deciphera’s New Drug Application for Vimseltinib for the Treatment of Patients with Tenosynovial Giant Cell Tumor (TGCT)

First quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

European Medicines Agency Accepts Deciphera's Marketing Authorization Application for Vimseltinib for Treatment of Patients with Tenosynovial Giant Cell Tumor (TGCT)

Final dividend of JP¥40.00 announced

Consensus EPS estimates fall by 23%

Full year 2024 earnings: EPS and revenues miss analyst expectations

Less than half of directors are independent

Price target decreased by 10% to JP¥2,336

Ono Pharmaceutical Co., Ltd. to Report Q1, 2025 Results on Jul 31, 2024

Ono Pharmaceutical Co., Ltd. (TSE:4528) completed the acquisition of Deciphera Pharmaceuticals, Inc. (NasdaqGS:DCPH) from BlackRock, Inc. (NYSE:BLK), Deerfield Capital, L.P., Redmile Group, LLC Brightstar Associates, LLC and others.

Consensus EPS estimates fall by 11%

Consensus EPS estimates fall by 10%

Full year 2024 earnings: EPS and revenues miss analyst expectations